生物制药公司Cidara Therapeutics, Inc.（股票代码：CDTX）今日盘前大涨93.41%，引发市场广泛关注。这一显著涨幅与市场传闻的重大收购交易密切相关。
据英国《金融时报》报道，制药巨头默克公司（Merck）正接近达成收购Cidara Therapeutics的交易。消息人士透露，如果没有最后障碍，这笔交易最快可能于今日正式宣布。虽然具体价格尚未披露，但据悉交易估值将超过33亿美元，大幅高于Cidara当前的市值。这一潜在收购反映了市场对Cidara在抗感染药物研发领域实力的高度认可。
值得注意的是，上个月Cidara的实验性药物CD388获得美国食品和药物管理局（FDA）授予的"突破性疗法"称号。该药物旨在预防甲型和乙型流感高危人群的重症，这一称号将加快药物的开发和审查进程。分析人士认为，如果收购最终达成，将为Cidara带来充足的资金支持其研发管线，并可能加速其产品的商业化进程。投资者和业内人士都将密切关注今日的进一步公告，以确认交易细节及其对公司未来发展的影响。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.